Analyst Tracker/Jonathan Wolleben

Jonathan Wolleben

Q: How accurate are Jonathan Wolleben's stock ratings?

About 49% of Jonathan's ratings were profitable over a one-year hold, with an average return of +11.8% per rating, measured by 13Foresight from historical prices.

Q: How is Jonathan ranked?

Jonathan Wolleben is ranked #170 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Citizens JMP

Wall Street Analyst

★★★★★

#170

on 13Foresight · ranked by our own returns

49%

Success Rate

+11.8%

Average Return

18 of 37 calls profitable · +55.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Jonathan Wolleben's ratings turned a profit when each position was held for 1 year — averaging +11.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

65 Buy 5 Hold 1 Sell

Jonathan's Stock Coverage 26 ratings · 2026-09-29

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
QNCX Quince Therapeutics	Sep 22, 2026	BUY	Buy +499.4% avg upside 18 analysts	$77.00 165.47% Upside	-1.1%	·
PHVS Pharvaris	Sep 09, 2026	BUY	Strong Buy +75.2% avg upside 15 analysts	$79.00 147.57% Upside	-12.6%	·
PTGX Protagonist Therapeutics	Aug 31, 2026	BUY	Strong Buy -15.6% avg upside 19 analysts	$170.00 19.40% Upside	-4.9%	·
SION Sionna Therapeutics, Inc.	Aug 10, 2026	HOLD	Buy +320.4% avg upside 12 analysts	—	+14.4%	·
GPCR Structure Therapeutics, Inc. Sponsored ADR	Aug 07, 2026	BUY	Strong Buy +194.9% avg upside 17 analysts	$110.00 213.75% Upside	-30.3%	·
BMEA Biomea Fusion	Aug 06, 2026	BUY	Strong Buy +924.9% avg upside 15 analysts	$7.00 442.58% Upside	+18.4%	·
MIRM Mirum Pharmaceuticals	Aug 06, 2026	BUY	Strong Buy +28.8% avg upside 22 analysts	$137.00 55.75% Upside	-4.7%	·
RYTM Rhythm Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +26.5% avg upside 22 analysts	$160.00 62.33% Upside	-10.9%	·
ANNX Annexon Biosciences	Jul 21, 2026	SELL	Strong Buy +256.3% avg upside 14 analysts	$3.00 25.26% Downside	+25.6%	·
MDGL Madrigal Pharmaceuticals	Jul 17, 2026	BUY	Strong Buy -0.2% avg upside 34 analysts	$739.00 42.84% Upside	-6.6%	·
DBVT DBV Technologies SA - American	Jun 30, 2026	BUY	Strong Buy +105.9% avg upside 15 analysts	$55.00 372.59% Upside	-29.0%	·
SGMT Sagimet Biosciences, Inc. Class A	May 19, 2026	BUY	Strong Buy +182.6% avg upside 17 analysts	$12.00 20.68% Upside	+65.1%	·
SPRB Spruce Biosciences	May 14, 2026	BUY	Strong Buy +117.9% avg upside 16 analysts	$150.00 215.65% Upside	-17.4%	·
ALT Altimmune	May 14, 2026	BUY	Strong Buy +775.6% avg upside 20 analysts	$11.00 271.69% Upside	+4.8%	·
IRD Opus Genetics	May 13, 2026	BUY	Strong Buy +138.8% avg upside 25 analysts	$11.00 117.88% Upside	-5.4%	·
KLRS Kalaris Therapeutics	May 13, 2026	BUY	Strong Buy +343.6% avg upside 13 analysts	$25.00 778.80% Upside	-36.4%	·
MBX MBX Biosciences, Inc.	May 12, 2026	BUY	Strong Buy +37.7% avg upside 14 analysts	$86.00 49.44% Upside	+55.0%	·
BCRX BioCryst	May 07, 2026	BUY	Strong Buy +113.3% avg upside 24 analysts	$28.00 230.64% Upside	-3.5%	·
PRQR ProQR	Mar 12, 2026	BUY	Strong Buy +575.4% avg upside 19 analysts	$8.00 384.89% Upside	-4.1%	·
OCUL Ocular Therapeutix	Feb 17, 2026	BUY	Strong Buy +210.8% avg upside 21 analysts	—	+42.9%	·
SVRA Savara	Oct 23, 2025	BUY	Strong Buy +71.8% avg upside 17 analysts	$11.00 116.89% Upside	+21.4%	·
LRMR Larimar Therapeutics	Oct 06, 2025	BUY	Strong Buy +464.8% avg upside 22 analysts	$18.00 467.73% Upside	-36.1%	·
SKYE Skye Bioscience	Oct 06, 2025	BUY	Strong Buy +2860.7% avg upside 9 analysts	$32.00 1887.52% Upside	·	·
AURA Aura Biosciences Inc	May 23, 2025	BUY	Strong Buy +233.5% avg upside 9 analysts	$19.00 209.04% Upside	+29.0%	·
RLYB Rallybio	Apr 23, 2025	HOLD	Buy +37.9% avg upside 8 analysts	—	+258.9%	·
WMG Warner Music Group	May 12, 2023	BUY	Strong Buy +33.8% avg upside 24 analysts	$24.00 11.51% Downside	+27.9%	·

🔒 21 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jonathan Wolleben — Frequently Asked Questions

How accurate are Jonathan Wolleben's stock ratings?

Based on the calls 13Foresight could measure, about 49% of Jonathan's ratings were profitable over a one-year hold, with an average return of +11.8% per rating, or +55.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Jonathan ranked on 13Foresight?

Jonathan Wolleben is currently ranked #170 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jonathan cover?

Jonathan most recently has ratings on QNCX, PHVS, PTGX, SION, GPCR, BMEA, MIRM, RYTM, ANNX, MDGL, DBVT, SGMT and 14 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Jonathan Wolleben

Rating Distribution

Welcome to 13Foresight!